Established guidelines recommend biopsying small tumors of the kidney ahead of any procedure to ablate them. A new study confirms the validity of pursuing another pathway.
Is portable MRI suitable for finding abnormalities in the brains of patients receiving new amyloid-targeting therapy for Alzheimer’s disease? Clinical researchers are about to find out.
There were no statistical differences in overall complication rates between the traditional and expedited groups, but there were marked savings and shorter hospital stays.
If generalizable AI models are to meaningfully contribute to precision cancer care, they’ll need to incorporate not only imaging data but also digitalized clinical notes, biomarker assays and monitor readouts.
Clinicians treating COVID-19 patients who have transplanted lungs and lower airway infection should order molecular testing in addition to, or regardless of, imaging findings.
An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.
Patients with autoimmune hepatitis may be better monitored across disease stages by AI-augmented multiparametric MRI than by liver biopsy, as the imaging has proven less costly and is inherently less risky due to its noninvasiveness.
With 91% sensitivity but only 25% specificity, the tool is worthwhile for clinicians who remain wary of frequent false positives that would send patients with no fractures for unneeded imaging.
A pharmaceutical compound approved 21 years ago to treat breast cancer in postmenopausal women is showing fresh promise as a therapy for glioblastomas.
"This was an unneeded burden, which was solely adding to the administrative hassles of medicine," said American Society of Nuclear Cardiology President Larry Phillips.
